Poor accrual is the leading cause of cancer clinical trial failure, most commonly affecting late-phase trials, but the factors associated with successful accrual remain poorly understood.1-3 We therefore sought to evaluate oncologic phase 3 trials using a mandatory web-based registration database as a means of identifying and quantifying factors associated with accrual completion.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Pasalic D, Tang C, Jagsi R, Fuller CD, Koong AC, Ludmir EB. Association of Industry Sponsorship With Cancer Clinical Trial Accrual. JAMA Oncol. 2020;6(10):1625–1627. doi:10.1001/jamaoncol.2020.1284
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: